NATIXIS ADVISORS, L.P. - TAKEDA PHARMACEUTICAL CO LTD ownership

TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 308 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.

Quarter-by-quarter ownership
NATIXIS ADVISORS, L.P. ownership history of TAKEDA PHARMACEUTICAL CO LTD
ValueSharesWeighting
Q3 2023$10,394
+0.1%
671,887
+1.6%
0.03%0.0%
Q2 2023$10,384
-8.7%
661,030
-4.3%
0.03%
-17.9%
Q1 2023$11,378
+1.8%
690,428
-3.6%
0.04%
-7.1%
Q4 2022$11,177
-99.9%
716,489
-6.6%
0.04%0.0%
Q3 2022$9,954,000
+14.7%
767,443
+24.1%
0.04%
+10.5%
Q2 2022$8,681,000
-0.9%
618,329
+1.1%
0.04%
+15.2%
Q1 2022$8,756,000
+59.2%
611,409
+51.5%
0.03%
+57.1%
Q4 2021$5,501,000
-41.1%
403,538
-29.2%
0.02%
-44.7%
Q3 2021$9,334,000
+5.5%
569,872
+8.4%
0.04%
-7.3%
Q2 2021$8,851,000
-5.4%
525,931
+2.6%
0.04%
-16.3%
Q1 2021$9,356,000
+60.9%
512,476
+60.4%
0.05%
+48.5%
Q4 2020$5,815,000
+15.0%
319,536
+12.7%
0.03%
+3.1%
Q3 2020$5,058,000
+5.6%
283,505
+6.1%
0.03%0.0%
Q2 2020$4,789,000
+15.5%
267,111
-2.2%
0.03%
-5.9%
Q1 2020$4,148,000
-0.6%
273,237
+29.1%
0.03%
+17.2%
Q4 2019$4,175,000
+29.4%
211,648
+12.8%
0.03%
+11.5%
Q3 2019$3,226,000
+28.9%
187,565
+32.6%
0.03%
+30.0%
Q2 2019$2,503,000
-14.5%
141,447
-1.6%
0.02%
-23.1%
Q1 2019$2,927,000
+1.3%
143,724
-16.4%
0.03%
+85.7%
Q4 2018$2,890,000171,8520.01%
Other shareholders
TAKEDA PHARMACEUTICAL CO LTD shareholders Q3 2020
NameSharesValueWeighting ↓
TFG Asset Management GP Ltd 1,903,662$29,449,6525.37%
MANAGED ASSET PORTFOLIOS, LLC 1,736,416$26,862,3564.12%
Y.D. More Investments Ltd 1,381,550$21,372,5794.11%
Clean Yield Group 533,157$8,167,9653.62%
XY Capital Ltd 143,697$2,222,9931.28%
Mondrian Investment Partners LTD 4,081,715$61,225,7251.26%
Capricorn Fund Managers Ltd 204,892$3,169,6791.10%
Legacy Wealth Asset Management, LLC 124,967$1,933,2390.71%
HAP Trading, LLC 263,679$4,079,1140.65%
BRANDES INVESTMENT PARTNERS, LP 1,802,036$27,877,4930.54%
View complete list of TAKEDA PHARMACEUTICAL CO LTD shareholders